Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113631334 | 11363133 | 4 | F | 20130310 | 20160719 | 20150810 | 20160722 | PER | PHHY2013US103273 | NOVARTIS | 60.96 | YR | M | Y | 0.00000 | 20160722 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113631334 | 11363133 | 1 | PS | GILENYA | FINGOLIMOD HYDROCHLORIDE | 1 | Oral | QD | U | 22527 | CAPSULE | QD | |||||||
| 113631334 | 11363133 | 2 | C | OSCAL D | CALCIUM CARBONATECHOLECALCIFEROL | 1 | Oral | U | 0 | ||||||||||
| 113631334 | 11363133 | 3 | C | ABTEI MAGNESIUM | 2 | Oral | 400 MG, BID | U | 0 | 400 | MG | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 113631334 | 11363133 | 1 | Multiple sclerosis |
| 113631334 | 11363133 | 2 | Osteopenia |
| 113631334 | 11363133 | 3 | Product used for unknown indication |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 113631334 | 11363133 | Anxiety | |
| 113631334 | 11363133 | Aspartate aminotransferase decreased | |
| 113631334 | 11363133 | Lymphocyte count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 113631334 | 11363133 | 3 | 20140608 | 0 |